SMILES string
O[C@@]1([C@@]2([C@H]([C@H]3[C@@H]([C@H]4CCC(=O)C=C4CC3)CC2)CC1)CC)C#C
InChI
1S/C21H28O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,13,16-19,23H,3,5-12H2,1H3/t16-,17+,18+,19-,20-,21-/m0/s1
InChI key
WWYNJERNGUHSAO-XUDSTZEESA-N
grade
pharmaceutical primary standard
API family
norgestrel
manufacturer/tradename
USP
application(s)
pharmaceutical (small molecule)
format
neat
正在寻找类似产品? 访问 产品对比指南
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Norgestrel USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Ethinyl Estradiol Tablets
- Levonorgestrel
- Norgestrel
- Norgestrel and Ethinyl Estradiol Tablets
- Norgestrel Tablets
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Other Notes
Sales restrictions may apply.
signalword
Danger
hcodes
Hazard Classifications
Eye Irrit. 2 - Repr. 1B - Skin Irrit. 2
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
涉药品监管产品
此项目有
Ondrej Mestak et al.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 28(10), 764-766 (2012-03-10)
We report the case of a female who had suffered from progressive lymphatic malformation in the orbito-temporal region since childhood. Many surgical interventions were performed, including radical excision and shunt drainage. Despite aggressive surgical treatment, recurrence was observed after every
Kai I Cheang et al.
Fertility and sterility, 96(2), 353-359 (2011-06-17)
To evaluate the effects of a commonly used combined hormonal oral contraceptive (OC) on carbohydrate metabolism in obese as compared with lean women. 6-month prospective study. Clinical research center at an academic medical center. Premenopausal nondiabetic women with body mass
Nozomi Donoyama et al.
Acupuncture in medicine : journal of the British Medical Acupuncture Society, 29(4), 304-306 (2011-10-22)
A 26-year-old top female athlete (height 157 cm), who took part in competitive sport similar to middle- and long-distance running, became amenorrhoeic in February 2009. In late May 2009, athletic amenorrhoea was diagnosed and a norgestrel-ethinyl estradiol combination (norgestrel 0.5
Lawrence Aderemi Olatunji et al.
Clinical hemorheology and microcirculation, 54(1), 23-31 (2012-06-01)
Oral contraceptive (OC) use and increased fructose feeding have been associated with altered cardiometabolic effects. The effect of increased dietary fructose during OC use on cardiometabolic parameters is unknown. We investigated the effects of a high-fructose diet on body weight
Jeffrey T Jensen et al.
The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception, 18(4), 274-283 (2013-05-04)
To determine the effect of oestradiol valerate/dienogest (E2V/DNG) versus ethinylestradiol/norgestimate (EE/NGM) on hormone-withdrawal associated symptoms (HWAS) in otherwise healthy women who had experienced at least one of these symptoms when using 21/7-day combined oral contraceptives (COCs). This phase III, parallel-group
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持